Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a single-institution, prospective phase II trial with an initial safety run-in to
evaluate the efficacy and safety of neoadjuvant pembrolizumab combined with chemoradiotherapy
and adjuvant pembrolizumab in patients with locally advanced esophageal and gastric cancers
(EGC). Chemoradiation therapy (45Gy in 25 fractions with concurrent, weekly carboplatin [AUC
2] and paclitaxel [50mg/m2 of BSA]) with three cycles of pembrolizumab will be administered
as neoadjuvant therapy. These patients will also receive three cycles of adjuvant
pembrolizumab after surgical resection